Key Takeaways
- Record revenue, margin expansion: Operating revenue hit an all-time high of INR 754 crores, up 10.6% YoY, while EBITDA margin expanded 217 bps YoY to 21.3%, driven by operating leverage and softer raw material costs.
- U.S. order book anchors growth ambition: The U.S. order book stands at $220 million plus, and management sees ~20% U.S. growth as achievable in the upcoming financial year once recent awards commercialize.
- Europe is the next big bet: Management called 2026 a turning point for Europe, with advanced M&A dialogues underway and new subsidiaries incorporated in Ireland and Canada; Germany operations began with two employees.
- Employee cost spike is temporary: Employee cost rose to ~15% of revenue as the new Goa facility hired ahead of utilization; management expects a reversion to the 13–13.5% norm by Q2 of next financial year as capacity fills.
- What to watch next quarter: Whether the U.S. order book begins converting to P&L, the pace of Europe M&A closure, and any stabilization in U.K. pricing as the cough-and-cold season plays through.
U.S. Performance & Order Book
- Strong quarter, geopolitical overhang easing: U.S. and North America revenue grew 24.2% YoY to INR 411.9 crores, supported by volumes and seasonal demand; non-seasonal products also showed decent growth. Management noted that 2025 was a "weird year" from April onward due to tariff uncertainty, but the resolution of that uncertainty is now a tailwind for customer conversations.
- Order book to revenue lag: Once an award is received, it takes approximately 5 to 6 months to commercialize; management expects the current $220 million-plus order book to begin trending into revenue by the first or second quarter of the next financial year.
- Growth target: Management stated that ~20% U.S. growth in the upcoming financial year is achievable, and the next order book milestone is $300 million by FY28.
- Tariff and policy risk contained: The Rx portfolio is very small relative to overall revenue, so the Trump administration's push on prescription drug pricing and OTC substitution does not change the U.S. strategy or materially impact the business.
Mark Saldanha: "Although we were not impacted by tariffs, but there has been a, I think it has basically put an ease to the uncertainty that prevailed in customers or consumers or clients' minds, right? So that is a big plus point that one could take away from this."
U.K. & Europe: Stabilization and Expansion
- U.K. flat but stabilizing: U.K. and EU revenue was flat YoY at INR 258.2 crores as pricing pressure persisted. Management sees price erosion bottoming out and expects stabilized performance in Q4, aided by seasonal demand in cough-and-cold and pain segments.
- New launches building gradually: Relonchem received MHRA marketing authorization for mefenamic acid tablets and cetirizine oral solutions. New launches have started contributing but are not yet significant; incremental revenue is expected on a QoQ basis.
- Europe build-out underway: Marksans Europe Limited was incorporated in Ireland, and the first two employees joined the Germany operation on 1 February. Management is filing 4–5 products every month in the U.K. and developing a portfolio of niche and complex molecules for broader Europe.
- M&A in advanced dialogue: The company is in advanced dialogue for acquisitions in European markets and expects 2026 to be a turning point, with a couple of deals possible. Target size depends on whether the company has pan-Europe distribution; better visibility on the quantum of spend is expected in the next 3–4 months.
Mark Saldanha: "I think 2026 will be a turning point where that is concerned. So we are quite hopeful that 2026, we may see a couple of M&As happening out there."
Margin Walk & Cost Structure
- Gross margin expanded 184 bps YoY to 58.1%, attributed to softening raw material prices, favourable product mix, and FX benefits. New higher-margin products have been launched but need time to scale; their contribution is partly negated by price erosion in the larger base portfolio.
- EBITDA margin expanded 217 bps YoY to 21.3%, driven by operating leverage and improved cost efficiencies. On a 9M basis, however, EBITDA margin declined to 19.4% from 21.2% in the prior year, reflecting a weak Q1 and costs associated with scale-up and integration.
- Employee cost spike is a utilization story: Employee cost moved from ~13% to ~15% of revenue because the new Goa facility hired to full strength while capacity utilization is still at around 50%. A INR 2.8 crore impact from new labour code accounting on gratuity also hit this quarter. Management expects the ratio to revert to 13–13.5% by Q2 of the next financial year as utilization rises, with no incremental hiring planned beyond annual increments and minimum wage adjustments.
- R&D spend rising with filings: R&D to sales will likely run between 2.5% and 3% next year, up from current levels, driven by aggressive U.K. filings and development of niche molecules for Europe. U.S. ANDA filings continue at a pace of 7–8 per year across different dosage forms.
Teva Facility & Capacity
- Operating leverage visible but below target: The Teva facility is trending at INR 560–600 crores in revenue against an objective of approximately INR 800 crores. The product mix needs to grow to close the gap.
- Capex trigger not yet pulled: A new block or plant capex of INR 150–200 crores has not been triggered because the company has not yet reached the benchmark utilization that would require it.
Mark Saldanha: "Operating leverage is very visible because of the Teva facility. We are trending around INR 560 crores to INR 600 crores odd from the Teva facility. Our objective was to hit about INR 800 crores odd."
New Geographies & Subsidiaries
- Canada incorporated, revenue next year: Marksans Canada Inc. was incorporated during the quarter. Hiring will begin this year, and revenue may start trickling in during the next financial year.
- Germany live, small start: The first two employees joined on 1 February; the team may grow in coming quarters. Market authorizations and wholesale licenses are being put in place and will take a couple of months before selling can begin.
- UAE acquisition performing: The UAE business is a standalone profit-making entity; the company has already recovered its return on the initial investment, with filings and approvals done and further returns yet to come.
- Australia & New Zealand strong: Revenue grew 30.1% YoY to INR 61.4 crores.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.S. revenue growth | ~20% growth achievable | Upcoming financial year (FY27) |
| U.S. order book conversion | Current $220 mn+ order book begins trending into P&L | Q1 or Q2 of next financial year |
| Employee cost to revenue | Revert to 13–13.5% (from ~15%) | By Q2 of next financial year |
| R&D to sales ratio | 2.5% to 3% | Next financial year |
| Revenue milestone | INR 4,000 crores (current portfolio only, excluding EU/Canada) | FY28 or FY29 |
| U.S. order book milestone | $300 million | By FY28 |
| Teva facility revenue | ~INR 800 crores | No date given; trending at INR 560–600 cr |
| Europe M&A | A couple of transactions possible; 2026 a turning point | 2026 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Operating revenue | ₹754 cr, +10.6% YoY, all-time high for the quarter |
| U.S. & North America revenue | ₹411.9 cr, +24.2% YoY, driven by volumes and seasonal demand |
| U.K. & EU revenue | ₹258.2 cr, flat YoY |
| Australia & New Zealand revenue | ₹61.4 cr, +30.1% YoY |
| Rest of World revenue | ₹22.4 cr |
| Gross margin | 58.1%, +184 bps YoY from 56.2%, driven by raw material softening, favourable product mix and forex benefits |
| EBITDA | ₹160.7 cr, +23.2% YoY |
| EBITDA margin | 21.3%, +217 bps YoY and +125 bps QoQ |
| Profit after tax | ₹113.7 cr, +8.2% YoY |
| EPS | ₹2.5 |
| 9M FY26 operating revenue | ₹2,094.8 cr, +9.4% YoY |
| 9M FY26 EBITDA margin | 19.4%, vs 21.2% in 9M FY25, reflecting weaker Q1, higher employee expenses and integration costs |
| 9M FY26 PAT | ₹271 cr; EPS ₹6.0 |
| U.S. order book | $220 million plus |
| Teva facility revenue | ₹560–600 cr trending, objective to reach ~₹800 cr |
| Cash balance | ₹824.2 cr as of 31st December 2025, debt-free |
| 9M FY26 cash from operations | ₹263.2 cr |
| 9M FY26 capex | ₹97 cr |
| Working capital | 151 days |
| 9M FY26 R&D spend | ₹62 cr, 3% of consolidated revenue |
| Employee cost impact from new labour code | ₹2.8 cr one-time impact on gratuity and new pay |
| Employee cost as % of revenue | ~15%, up from 13% in FY23, driven by Goa facility hiring at ~50% utilization |
| U.K. filings pace | 4–5 products per month |
| U.S. ANDA filings pace | 7–8 ANDAs per year |
| Canada portfolio mix | 80% OTC, 20% Rx |
| Europe portfolio mix | ~90% Rx, ~10% OTC |
| Revenue milestone target | ₹4,000 cr in next 2–3 years, FY28 or FY29 |
| U.S. order book target by FY28 | $300 million (per management discussion) |
| U.S. revenue growth outlook | ~20% in upcoming financial year, management said "very close to that" |
| Regular annual capex | ₹50–60 cr on optimizations; new plant capex could be ₹150–200 cr if triggered |
| Cash split | ~50% India books, ~40% U.K. books, rest across U.S. and Australia |
| Reclassification impact | ~₹8 cr reclassified from other income to other expenditure in base quarter for mark-to-market forex provision |